Affimed (NASDAQ:AFMD) Price Target Lowered to $4.00 at Stifel Nicolaus

Affimed (NASDAQ:AFMD) had its price objective trimmed by Stifel Nicolaus from $5.00 to $4.00 in a report released on Friday morning,Benzinga reports. The firm currently has a hold rating on the biopharmaceutical company’s stock.

Several other research firms also recently commented on AFMD. Cantor Fitzgerald reissued an “overweight” rating on shares of Affimed in a research note on Monday, September 9th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Affimed in a report on Friday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $16.00.

Affimed Stock Down 4.7 %

AFMD stock traded down $0.17 during midday trading on Friday, hitting $3.48. 132,609 shares of the stock traded hands, compared to its average volume of 266,981. The stock’s fifty day simple moving average is $3.49 and its 200-day simple moving average is $4.52. The company has a quick ratio of 2.71, a current ratio of 2.71 and a debt-to-equity ratio of 0.13. Affimed has a 1-year low of $2.92 and a 1-year high of $8.95.

Affimed (NASDAQ:AFMD) last posted its quarterly earnings data on Thursday, September 5th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.09). Affimed had a negative net margin of 2,922.74% and a negative return on equity of 155.30%. The business had revenue of $0.17 million during the quarter, compared to analysts’ expectations of $1.67 million. As a group, analysts anticipate that Affimed will post -4.25 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Jane Street Group LLC purchased a new position in Affimed in the 3rd quarter valued at $44,000. Choreo LLC purchased a new stake in shares of Affimed in the second quarter valued at about $54,000. FMR LLC increased its stake in shares of Affimed by 30.0% during the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 4,086 shares during the period. Intellectus Partners LLC raised its holdings in Affimed by 12.2% during the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after purchasing an additional 10,250 shares in the last quarter. Finally, Point72 Asset Management L.P. lifted its position in Affimed by 4.6% in the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after purchasing an additional 15,108 shares during the period. Institutional investors and hedge funds own 30.82% of the company’s stock.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.